Study of INCB123667 in Subjects With Advanced Solid Tumors

Active:	Yes
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT05238922
Trial Phases:	Phase I	Protocol IDs:	INCB 123667-101 (primary) NCI-2022-03370
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Incyte Corporation
NCI Full Details:	http://clinicaltrials.gov/show/NCT05238922

Summary

This is an open-label, dose-escalation and dose-expansion study to determine the safety,
tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered
as monotherapy at the RDE(s) in participants with selected advanced or metastatic solid
tumors. Part 1A (dose escalation) will determine the recommended dose of INCB123667 for
expansion (RDE) and the maximum tolerated dose (MTD). Part 1B (cohort dose expansion phase)
will further explore antitumor activity of INCB123667 as a monotherapy in 6 tumor-specific
cohorts at the RDE(s) defined in Part 1A.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.